Curated News
By: NewsRamp Editorial Staff
October 21, 2025
Oragenics Regains NYSE Compliance, Advances Concussion Drug Trials
TLDR
- Oragenics regained NYSE compliance and secured $16.5 million funding, positioning investors to benefit from advancing ONP-002 through key clinical trials.
- Oragenics restored compliance by meeting NYSE standards through a public offering that funded equity and supports Phase II trials for their intranasal brain therapy.
- Oragenics' brain-targeted intranasal technology aims to revolutionize neurological care, potentially improving recovery for concussion patients and advancing treatments for CNS disorders.
- Oragenics is developing the first FDA-approved intranasal treatment for concussion using proprietary technology that delivers therapeutics directly to the brain.
Impact - Why it Matters
This development matters because Oragenics' progress represents a critical step forward in neurological medicine, particularly for concussion treatment where no FDA-approved pharmaceutical options currently exist. For millions of people who suffer concussions annually—from athletes to accident victims—the advancement of ONP-002 could provide the first evidence-based treatment option rather than relying solely on rest and symptom management. The company's regained compliance and successful funding round also signal financial stability and investor confidence, which is crucial for advancing expensive clinical trials in the biotechnology sector. Furthermore, their intranasal delivery platform technology has broader implications for treating other neurological conditions like Alzheimer's and Parkinson's disease, potentially revolutionizing how brain-targeted therapies are administered without invasive procedures.
Summary
Oragenics (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, has achieved a significant corporate milestone by regaining full compliance with NYSE American's continued listing standards. The exchange confirmed on October 20, 2025, that the company now meets Section 1003(a)(iii) requirements, removing the below-compliance indicator and restoring Oragenics to the roster of compliant issuers. CEO Janet Huffman emphasized that this achievement represents more than just regulatory compliance, stating it reflects the company's commitment to transparency, financial discipline, and restoring investor confidence. This regulatory victory follows the successful July 2, 2025, closing of a $16.5 million public offering of Series H Convertible Preferred Stock, which restored stockholder equity and provides crucial funding for advancing the company's lead candidate through critical development phases.
The company's primary focus remains on ONP-002, their groundbreaking therapeutic candidate advancing with the ambitious goal of becoming the first FDA-approved treatment for concussion. The newly secured funding will support key Phase II milestones in Australia and upcoming Phase IIb trials in the United States, representing significant progress in the drug development pipeline. Oragenics' proprietary intranasal delivery technology platform has the potential to revolutionize neurological care by enabling targeted, non-invasive therapeutics for brain-related conditions. Beyond concussion treatment, the company believes their platform technology could open pathways to address neurodegenerative diseases, CNS disorders, and other neurological conditions, positioning them at the forefront of brain-first recovery innovation. The company maintains its newsroom through the BioMedWire platform, which serves as part of the broader Dynamic Brand Portfolio within the IBN network, providing comprehensive corporate communications solutions and distribution to thousands of outlets.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Oragenics Regains NYSE Compliance, Advances Concussion Drug Trials
